FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L. Suzman, Julia A. Beaver, Laura L. Fernandes et al.|The Oncologist|2018Cited by 200
Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval SummaryYang‐Min Ning, Richard Pazdur, William F. Pierce et al.|Clinical Cancer Research|2013Cited by 67